Recent lab results proved the Company’s hypothesis that disguising cancer cells to look like common infectious diseases can trick immune cells into attacking the malignant cells
Recent lab results proved the Company’s hypothesis that disguising cancer cells to look like common infectious diseases can trick immune cells into attacking the malignant cells
"Driving Innovation Across Healthcare, Agriculture, and Environmental Science, Microbiome Sequencing Unlocks the Power of Microbial DNA to Enable Personalized Medicine, Sustainable Farming, and Ecosystem...
"Driving Innovation Across Healthcare, Agriculture, and Environmental Science, Microbiome Sequencing Unlocks the Power of Microbial DNA to Enable Personalized Medicine, Sustainable Farming, and Ecosystem...
World's most successful athletic fundraiser aims to raise record $76 million
BOSTON, Aug. 2, 2025 /PRNewswire/ -- This weekend, the Pan-Mass Challenge (PMC) unites more than...
Clinical Stage Biotechnology Company Uses Patient Immune System to "Seek and Destroy" Cancer and Metastasis
SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- Res Nova Biologics,...
REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results
BINYAMINA, Israel and CARY, N.C., July 30, 2025 /PRNewswire/ -- OncoHost, a leader in precision oncology leveraging proteomics and AI to personalize cancer care, today...
The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...
The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...
Alan Korman honored in the category of tumor immunology for foundational role in checkpoint inhibitors
PITTSBURGH, July 29, 2025 /PRNewswire/ -- BlueSphere Bio, a clinical...